Global Auto-Injectors Revenue Is Nearly 1660 Million USD And The Actual Sales Are About 17 Million Units In 2017
Thursday, 08 Nov, 2018
In the last several years, global market of Auto-Injectors developed rapidly, with an average growth rate of 5.04%. In 2017, global revenue of Auto-Injectors is nearly 1660 Million USD; the actual sales are about 17 million units.
Auto-Injectors are expected to present vast opportunities to investors due to high demand in biologics development. Overall revenues from the pre-filled syringes segment is expected to grow during the forecast period due to the rising need for targeted and sustained drug delivery.
The global average price of Auto-Injectors is in the increasing trend from 2013-2016, Auto-injectors manufacturers are introducing generic versions in order to reduce the overall cost of the device. In order to better serve anaphylaxis patients with epinephrine at an affordable cost, Mylan N.V. has implemented the decision of introducing the generic version of Epipen at half the price. The initial pack of two was sold at US$ 600 till December 2016 which will be sold at US$ 300 from January 2017. This has increased the affordability of insured as well as non-insured patients to opt for Epipen.
The classification of Auto-Injectors includes reusable Auto-Injectors and disposable Auto-Injectors, and the proportion of disposable Auto-Injectors in 2017 is about 62.7%, and the proportion is in increasing trend from 2013 to 2017.
Auto-injectors are pen like devices used to deliver a fixed dose of drug to patients and are intended for self-administration. Auto-injectors are gradually becoming the gold-standard in the treatment of various indications like anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The most proportion of Auto-Injectors is used for Anaphylaxis, and the proportion in 2017 is 56.9%.
North America is the largest consumption place, with a consumption market share nearly 59.5% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 20%. China is also an important sales region.
Market competition is not intense. Mylan, BD, Johnson & Johnson, Amgen?Inc., etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.